Laurus Labs

CDMO stocks in focus: Laurus Labs hits new high; Sai Life Sciences gains 2%

In the past one month, Laurus Labs and Sai Life shares have surged 18 per cent and 15 per cent, respectively. In comparison, the BSE Sensex has slipped 4.2 per cent.

Marico, Nestle, Laurus, Grasim and 15 others from Nifty 500 hit new highs

Vijaya Diagnostic Centre was quoting higher for the eight straight trading day, soaring 25 per cent during the period.

Laurus, Sai Life Sciences up 3% in weak market; what's driving CDMO stocks?

In the past one month, Laurus (up 14 per cent) and Sai Life (up 15 per cent) have outperformed the market by soaring up to 15 per cent

Nifty Pharma hits 52-wk high; Wockhardt up 15%, Laurus, Lupin at new peaks

The Nifty Pharma index was quoting higher for the fifth straight trading day, surging 3.8 per cent during the period, as against 0.37 per cent gain in Nifty 50.

Laurus Labs rallies 6%, hits record high post Q4 results; brokerages upbeat

Laurus Labs is now getting the benefit of the same as the CDMO quarterly run rate has gone up from ₹220-250 crore to ₹450-500 crore in two years, believe analysts.

Nifty Pharma index soars 3%; Dr Reddy's, Piramal Pharma rally up to 9%

Glenmark Pharma, Cipla, Wockhardt, Mankind Pharma, Lupin, Zydus Life, Laurus, Ipca Labs, Divis Labs, Strides Pharma and Onesource were up in the range of 3% to 6%.

Trading guide: Nifty eyes 23,200; BSE, Laurus Labs, Cipla on analyst radar

Stocks to buy: Ajit Mishra of Religare Broking recommends buying BSE and Laurus Labs; also suggests Nifty trading strategy

Laurus Labs jumps 4% on huge volumes; Motilal projects 30% further upside

Motilal Oswal remains positive on Laurus due to its strengthening position in gaining CDMO contracts, the addition of a growth lever in the generics space, and a steady ARV business.

Laurus Labs soars 8% in 2 days, nears record high; analysts see more upside

The management expects better Q4 and a decent overall growth in FY27

Stocks to buy: Graphite India, Laurus Labs, Tata Steel are on analyst radar

Stocks to buy today, February 26, 2026: Kunal Kamble of Bonanza Portfolio recommends buying Laurus Labs, Tata Steel, and Graphite India; here's why

Indian CRDMO market to outpace APAC; HDFC Sec starts coverage on top firms

While HDFC Securities has assigned a 'Buy' rating to Divi's Labs, Sai Life Sciences, and Piramal Pharma, it has given an 'Add' rating to Anthem BioSciences and a 'Reduce' rating to Laurus Labs

Pharma index hits 52-week high; Glenmark, Lupin rally 3% in subdued market

In the past two trading days, the Nifty Pharma index has rallied 3.3 per cent, as compared to 0.41 per cent decline in the Nifty 50.

Laurus zooms 82% so far in 2025; set for best yearly performance in 5 years

The stock hit a new high of ₹1,095, appreciated 117% from its 52-week low of ₹504.30 touched on January 28, 2025.

Laurus Labs zooms 73% in 2025, hits new high; what's driving pharma stock?

Laurus Labs management said the fundamentals of the company's business remain strong, with sustained growth momentum in the Contract Development and Manufacturing Organization and Generic business.

7 stocks gain up to 104% in FY26 as PAT up over 50% in Q1, Q2; Buy or sell?

BSE, Hitachi Energy, GE Vernova, Syrma SGS, Force Motors, HBL Engineering and Laurus Labs have gained more than 50% each after these companies reported over 50% growth in profit in Q1 and Q2 of FY26.

Dividend stocks: Coforge, Laurus Labs, 5 others to remain in focus today

Among the companies trading ex-dividend on Friday, Coforge has declared an interim dividend of ₹4 per share, with the record date set for the same day

M&M, HDFC Bank, Laurus Labs among Motilal Oswal's top growth bets; Check TP

HDFC Bank (HDFCB) reported a steady Q2FY26, with profit rising 11 per cent Y-o-Y to ₹186.4 billion, aided by healthy NII of ₹315.5 billion and strong treasury gains of ₹23.9 billion

Laurus zooms 105% in 1 year, hits new high. Should you buy, hold or sell?

Thus far in the month of October 2025, Laurus Labs has outperformed the market by surging 14 per cent.

Laurus Labs shares drop 3% despite analysts' bullish outlook; details here

Laurus Labs reported a strong Q2 FY26 performance, with consolidated net profit soaring multifold to ₹194.97 crore, compared with ₹19.78 crore in Q2 FY25

Q2 results today: HUL, Colgate, Laurus Labs among 11 firms on Oct 23

Q2FY26 company results: Many firms including PTC India Financial Services, Tata Teleservices, Jumbo Bag and Vardhman Textiles are also to release their July-September quarter earnings reports today